Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in LondonGlobeNewsWire · Oct 14, 2026
Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial AnalysisDefense World · Oct 4, 2026
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026GlobeNewsWire · Oct 2, 2026
Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest BetSeeking Alpha · Sep 30, 2026
Century Therapeutics Appoints Joseph Truitt to Board of DirectorsGlobeNewsWire · Sep 9, 2026
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesGlobeNewsWire · Aug 12, 2026Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.11 | -$0.17 | Miss |
| May 13, 2026 | -$0.15 | -$0.11 | Beat |
| Mar 12, 2026 | -$0.28 | -$0.25 | Beat |
| Nov 13, 2025 | -$0.39 | -$0.32 | Beat |
| Aug 14, 2025 | -$0.38 | -$0.38 | Beat |
| May 15, 2025 | -$0.31 | $0.89 | Beat |